SCPH240719C2500
- 2.20
- +0.20+10.00%
scPharmaceuticals Newsroom
Craig-Hallum Maintains ScPharmaceuticals(SCPH.US) With Buy Rating
Craig-Hallum analyst Chase Knickerbocker maintains $scPharmaceuticals(SCPH.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 43.5% and a total average return of 2.7%
These 2 'Strong Buy' Penny Stocks Are Poised for a Massive Rally, Say Analysts
ScPharmaceuticals to Present at the Jefferies Global Healthcare Conference
BURLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of
Analysts Have Conflicting Sentiments on These Healthcare Companies: ScPharmaceuticals (SCPH), Andlauer Healthcare Group (OtherANDHF) and Roche Holding AG (OtherRHHVF)
Furoscix Growth Prospects Anchor Buy Rating for ScPharmaceuticals
Analysts Are Bullish on These Healthcare Stocks: ScPharmaceuticals (SCPH), Optinose (OPTN)
Express News | HC Wainwright & Co. Reiterates Buy on ScPharmaceuticals, Maintains $18 Price Target
ScPharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 291.3% HC Wainwright & Co. → $18 Reiterates Buy → Buy 03/14/2024 291.3% HC Wainwright & Co. → $
Analysts Offer Insights on Healthcare Companies: Alcon (ALC), ScPharmaceuticals (SCPH) and Ascendis Pharma (ASND)
Buy Rating Affirmed for ScPharmaceuticals Amid Furoscix Success and Market Expansion
scPharmaceuticals | 10-Q: Quarterly report
Express News | ScPharmaceuticals Q1 2024 GAAP EPS $(0.36) Beats $(0.44) Estimate, Sales $6.10M Beat $5.98M Estimate
ScPharmaceuticals: Anticipate Gross To Net Discount Will Increase, May Approach 30% to 35% by the End of This Yr >SCPH
ScPharmaceuticals: Anticipate Gross To Net Discount Will Increase, May Approach 30% to 35% by the End of This Yr >SCPH
Express News | ScPharmaceuticals Q1 Net Income USD -14.108 Million Vs. Ibes Estimate USD -17.4 Million
Express News | ScPharmaceuticals Q1 Operating Expenses USD 21.958 Million
Express News | ScPharmaceuticals Q1 Income From Operations USD -15.856 Million Vs. Ibes Estimate USD -16.1 Million
ScPharmaceuticals 1Q Loss $14.1M >SCPH
ScPharmaceuticals 1Q Loss $14.1M >SCPH
Express News | ScPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
Notable Earnings After Tuesday's Close
ScPharmaceuticals to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
BURLINGTON, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of